Category: Finance
-
Funds Awarded for Astronaut Eye Disorder Technologies
9 March 2015. Three companies are each receiving $100,000 in early-stage funds from a challenge seeking technologies to diagnose or correct eye problems in space faced by astronauts. The awards are made by National Space and Biomedical Research Institute (NSBRI) at Baylor College of Medicine in Houston, from its Vision for Mars Challenge. The Vision…
-
Biomedical Applications for Nanofibers Sought in Challenge
6 March 2015. A new challenge on InnoCentive is seeking novel ways of using unique properties of nanofibers to treat human diseases. The competition as a total purse of $10,000 and a deadline of 3 April 2015. InnoCentive in Waltham, Massachusetts conducts open-innovation, crowdsourcing competitions for corporate and organization sponsors. The sponsor, in this case,…
-
Gates Invests, Supports R&D in RNA Vaccine Maker
6 March 2015. The Bill and Melinda Gates Foundation is making an equity investment and providing a grant to support research at CureVac GmbH, a developer of vaccines and therapies with RNA molecules. The foundation is investing €46 million ($52 million) in CureVac, in Tübingen, Germany, but the amount of the grant supporting research in…
-
Illumina Adds $40M for Genomic Accelerator Start-Ups
26 February 2015. Illumina Inc., a developer of genomic analysis systems, is adding $40 million for investments in new enterprises based on genomic science that graduate from its accelerator program. The additional financing is provided by Viking Global Investors, an equity and hedge fund investment company in Greenwich, Connecticut. The Illumina Accelerator program provides promising…
-
Bristol-Myers Squibb Acquires Biotech Cancer Therapies
24 February 2015. Bristol-Myers Squibb is purchasing biotechnology company Flexus Biosciences Inc., gaining many of that company’s cancer therapies in a deal valued as much as $1.25 billion to Flexus’s shareholders. The deal allows Flexus Biosciences shareholders to spin-off a new enterprise to develop the remaining drug programs, including treatments for cancer. The acquisition gives…
-
Challenge Seeks Extended Release Intravenous Drug Delivery
20 February 2015. A new challenge on InnoCentive is seeking ways to administer high-dose drugs through intravenous delivery, but releasing the therapy in the patient for a period of 8 to 10 hours. The competition has a purse of $30,000 and deadline of 21 March 2015. InnoCentive in Waltham, Massachusetts conducts open-innovation, crowdsourcing competitions for…
-
Redesigned Crutch Developer Gains $450K in Early Funds
17 February 2015. A company developing a more comfortable alternative to standard underarm or forearm crutches, secured $450,000 in its first venture funding round. Financing for Better Walk Inc., a spin-off from Georgia Institute of Technology and based in Atlanta, is led by MB Venture Partners, a Memphis-based venture capital firm. A broken ankle playing basketball…
-
Image Analysis Company Raises $800K for New Venture
16 February 2015. Glencoe Software Inc., a developer of image analysis and management software for research and pharmaceutical applications, raised $800,000 to fund a new venture in digital pathology. Financing for the Seattle company’s venture is provided by TIE Angels Group – Seattle and several other local angel investors. Glencoe is the commercialization arm of…
-
Intrexon Acquires Biopharm Company for $60M
13 February 2015. Intrexon Corp., a biotechnology company in Gaithersburg, Maryland specializing in synthetic biology, is acquiring ActoGeniX, developing biologic therapies from engineered microbes. Under the deal, stockholders of ActoGeniX, based in Ghent, Belgium, are receiving $30 million in cash plus another $30 million in Intrexon stock. ActoGeniX develops therapies from engineered microbes, particularly Lactococcus…
-
Foundation, Pfizer Collaborate on Alzheimer’s Targets
11 February 2015. Alzheimer’s Drug Discovery Foundation and Pfizer’s Centers for Therapeutic Innovation are joining forces to sponsor research to find new Alzheimer’s disease drug targets. Financial details of the collaboration were not revealed. The foundation and Pfizer plan to invest in project teams of Pfizer and academic scientists to translate academic research into candidates…